With an exclusive global alliance worth up to $205 million plus double-digit royalties to develop and commercialize Alnylam Pharmaceuticals' ALN-PCS, the RNAi specialist and The Medicines Company are in a crowded field of companies with hypercholesterolemia therapies targeting proprotein convertase subtilisin/kexin type 9 (PCSK9), which regulates low-density lipoprotein (LDL).
The partners have a long way to run to catch up with the seven antibody developers that are developing PCSK9...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
